Hyperparathyroidism and long-term bone loss after renal transplantation

被引:64
作者
Heaf, J
Tvedegaard, E
Kanstrup, IL
Fogh-Andersen, N
机构
[1] Univ Copenhagen Hosp, Dept Nephrol, Herlev, Denmark
[2] Univ Copenhagen Hosp, Dept Clin Physiol, Herlev, Denmark
[3] Univ Copenhagen Hosp, Dept Clin Biochem, Herlev, Denmark
关键词
bone mass; cyclosporine; dual X-ray absorptionometry; osteocalcin; parathyroid hormone; renal transplantation; steroids; vitamin D;
D O I
10.1034/j.1399-0012.2003.00047.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: While early bone loss after renal transplantation (RT) is well described, factors affecting the long-term fate of bone have received less attention. Methods: Whole body (WB), lumbar spine (LS) and femoral neck (FN) bone mineral density (BMD) was measured using dual energy X-ray absorptionometry in 126 stable RT patients and repeated in 114 survivors after 3 yr. Percentage change per year (%/yr) was correlated to clinical and biochemical markers of bone metabolism. Results: Low bone mass was a marker of increased mortality (FN<80% normal 6.3%/yr; >80% 2.2%/yr). Percent change was WB -0.7+/-1.5 (p<0.01); LS -0.3+/-2.6; FN -1.0+/-3.0 (p<0.01) and, corrected for expected loss for age and sex: WB -0.5 (p<0.01); LS 0.0; FN-0.8 (p<0.05). Factors associated with increased loss rates were (LS%): short RT duration [<2 yr: -3.1 (p<0.01)], high prednisone dose [>9 mg/d:-1.9 (p<0.01)], high cyclosporine trough concentration [>175 ng/L: -1.9 (p<0.05)], high hyperparathyroidism (PTH) [>150 ng/L: -1.5 (p<0.05)], high alkaline phosphatase [>275 U/L: -1.6 (p<0.05)], high osteocalcin [>75 mug/L: -1.6 (p<0.05)]. Marginal detrimental effects of uremia, hypoalbuminemia and hyperphosphatemia were noted. Thiazide treatment seemed to protect against, and furosemide to exacerbate, bone loss, but this may have been related to associated uremia. Patients treated with vitamin D gained bone, while untreated patients with low initial 1,25-dihydroxyvitamin D lost bone [FN%-2.1 (p<0.05)]. The prevalence of PTH (52%) and hypercalcemia (22%) remained unchanged. There was no effect of sex hormone levels, calcium and phosphate excretion, or serum calcium. Conclusion: While LS BMD stabilizes after RT, there is a continuing loss of WB and FN BMD. The major causes of bone loss are steroid therapy and continuing PTH, with no tendency towards spontaneous resolution. Increased vitamin D and calcium therapy should be considered for this patient group, and more aggressive therapy, e.g. parathyroidectomy given for patients with resistant PTH of >150 ng/L.
引用
收藏
页码:268 / 274
页数:7
相关论文
共 21 条
[1]   Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism [J].
Abdelhadi, M ;
Nordenstrom, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3845-3851
[2]   Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation [J].
Cueto-Manzano, AM ;
Konel, S ;
Freemont, AJ ;
Adams, JE ;
Mawer, B ;
Gokal, R ;
Hutchison, AJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (02) :227-236
[3]   THE DELETERIOUS EFFECTS OF LONG-TERM CYCLOSPORINE-A, CYCLOSPORINE-G, AND FK506 ON BONE-MINERAL METABOLISM IN-VIVO [J].
CVETKOVIC, M ;
MANN, GN ;
ROMERO, DF ;
LIANG, XG ;
MA, YF ;
JEE, WSS ;
EPSTEIN, S .
TRANSPLANTATION, 1994, 57 (08) :1231-1237
[4]  
D'Angelo A, 2000, CLIN NEPHROL, V53, pB19
[5]   No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients [J].
Dumoulin, G ;
Hory, B ;
Nguyen, NU ;
Bresson, C ;
Fournier, V ;
Bouhaddi, M ;
Chalopin, JM ;
SaintHillier, Y ;
Regnard, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (05) :746-753
[6]   Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer [J].
Fraser, WD ;
Durham, BH ;
Berry, JL ;
Mawer, EB .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :632-637
[7]   Alendronate prevents further bone loss in renal transplant recipients [J].
Giannini, S ;
D'Angelo, A ;
Carraro, G ;
Nobile, M ;
Rigotti, P ;
Bonfante, L ;
Marchini, F ;
Zaninotto, M ;
Carbonare, LD ;
Sartori, L ;
Crepaldi, G .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (11) :2111-2117
[8]  
GROTZ WH, 1995, NEPHROL DIAL TRANSPL, V10, P2096
[9]   Treatment of osteopenia and osteoporosis after kidney transplantation [J].
Grotz, WH ;
Rump, LC ;
Niessen, A ;
Schmidt-Gayk, H ;
Reichelt, A ;
Kirste, G ;
Olschewski, M ;
Schollmeyer, PJ .
TRANSPLANTATION, 1998, 66 (08) :1004-1008
[10]   Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease [J].
Heaf, J ;
Tvedegaard, E ;
Kanstrup, IL ;
Fogh-Andersen, N .
CLINICAL TRANSPLANTATION, 2000, 14 (05) :457-463